The Role of Fibroscan in Assessment of Liver Fibrosis in Patients With Diabetes Mellitus and Metabolic Dysfunction Associated Steatotic Liver Disease (MASLD)

被引：0
|
作者：
Menon, Raakhi [1 ]
Movva, Giri [1 ]
Garza, Devin [1 ]
Butt, Edward [1 ]
Zhang, Julia [1 ]
Khan, Kashif [1 ]
机构：
[1] Univ Texas Med Branch, Galveston, TX USA
来源：
AMERICAN JOURNAL OF GASTROENTEROLOGY | 2024年 / 119卷 / 10S期
关键词：
D O I：
10.14309/01.ajg.0001036180.44221.bc
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
S1703
引用
收藏
页码：S1240 / S1240
页数：1
相关论文
共 50 条
  • [1] Evaluation of liver fibrosis and steatohepatitis associated with metabolic dysfunction (MASH) in patients with inflammatory bowel disease (IBD) and steatotic liver disease associated with metabolic dysfunction (MASLD)
    Oliveira, E. C. S. D.
    Lopes, M. A.
    Beraldo, R. F.
    Castelhano, N. S.
    Baima, J. P.
    Herrerias, G. S. P.
    Quaglio, A. E., V
    Di Stasi, L. C.
    Barbosa, W. F.
    Silva, G. F.
    Sassaki, L. Y.
    JOURNAL OF CROHNS & COLITIS, 2025, 19 : i666 - i666
  • [2] Adipocytokines as Predictors of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) Development in Type 2 Diabetes Mellitus Patients
    Fajkic, Almir
    Jahic, Rijad
    Hadzovic-Dzuvo, Almira
    Lepara, Orhan
    CUREUS JOURNAL OF MEDICAL SCIENCE, 2024, 16 (03)
  • [3] SUBOPTIMAL ASSESSMENT OF FIBROSIS IN PATIENTS WITH METABOLIC DYSFUNCTION-ASSOCIATED STEATOTIC LIVER DISEASE (MASLD) IN PRIMARY CARE VERSUS LIVER CLINIC SETTINGS
    Nguyen, Brian T.
    Nguyen, Vy H.
    Park, Jung Eun
    Gudapati, Surya T.
    Maeda, Mayumi
    Kam, Leslie Y.
    Cheung, Ramsey
    Nguyen, Mindie H.
    GASTROENTEROLOGY, 2024, 166 (05) : S1651 - S1652
  • [4] INSULIN RESISTANCE IS A PREDICTOR OF METABOLIC DYSFUNCTION-ASSOCIATED STEATOTIC LIVER DISEASE (MASLD) AND MASLD-ASSOCIATED FIBROSIS
    Kim, David S.
    Ismail, Mohamed
    Abboud, Yazan
    Khan, Wajiha
    Le, Alexander
    Pyrsopoulos, Nikolaos T.
    Kim, Hyunseok
    Hajifathalian, Kaveh
    GASTROENTEROLOGY, 2024, 166 (05) : S1657 - S1657
  • [5] Cardioprotective Role of Beta Hydroxybutyrate in Metabolic Dysfunction -Associated Steatotic Liver Disease (MASLD)
    Badmus, Olufunto
    da Silva, Alexandre
    Taylor, Lucy
    Greer, Jennifer
    McGowan, Karis
    PHYSIOLOGY, 2024, 39
  • [6] Diagnosis and evaluation of metabolic dysfunction associated steatotic liver disease (MASLD)
    Canivet, C. M.
    Faure, S.
    REVUE DE MEDECINE INTERNE, 2024, 45 (01): : 41 - 47
  • [7] Subclinical myocardial fibrosis is related to disease severity in patients with metabolic dysfunction-associated steatotic liver disease (MASLD)
    Nabilou, Puria
    Wiese, Signe
    Hetland, Liv
    Werge, Mikkel
    Thing, Mira
    Rashu, Elias
    Junker, Anders
    Barlose, Mads
    Siebner, Hartwig
    Moller, Soren
    Bendtsen, Flemming
    Gluud, Lise Lotte
    Hove, Jens
    JOURNAL OF HEPATOLOGY, 2024, 80 : S555 - S555
  • [8] The non-invasive assessment of liver fibrosis in metabolic dysfunction associated steatotic liver disease (MASLD) in the chinese population: a scoping review
    Wei, Lai
    Cao, Di
    Qi, Xuan
    Wang, Ying
    Nan, Yuemin
    JOURNAL OF HEPATOLOGY, 2024, 80 : S558 - S558
  • [9] Real world evaluation of a primary care pathway for the assessment of liver fibrosis in metabolic dysfunction-associated steatotic liver disease (MASLD)
    Ahmad, Basil
    Mitchell, Oliver
    Pannifex, Sally
    Singanayagam, Arjuna
    Hughes, Sarah
    Clark, Sarah
    Yalcin, Metin
    Williams, Nicola
    Davie, Sarah
    Forton, Daniel
    JOURNAL OF HEPATOLOGY, 2024, 80 : S523 - S523
  • [10] Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) in Italian women: is liver fibrosis independent from menopause?
    Chen, R.
    Salamone, A.
    Abbati, C.
    Capelli, R.
    Santangeli, E.
    Stefanini, B.
    Indre, M. G.
    Ravaioli, F.
    Piscaglia, F.
    Ferri, S.
    DIGESTIVE AND LIVER DISEASE, 2025, 57
12345